Mexico pharmaceutical and healthcare market developments

The Mexican pharmaceutical and healthcare sectors are navigating a complex landscape of significant financial liabilities and market expansion. The federal government has officially recognized a debt of 110.8 billion pesos owed to the pharmaceutical industry, an amount representing roughly 63 percent of the projected 2026 budget for IMSS-Bienestar. Industry groups, including Amelaf and Concamin, have called for immediate liquidation of these debts, warning that delayed payments could lead to shortages of essential supplies in hospitals and clinics. These groups also expressed concerns that competition from subsidized suppliers in India and China creates an uneven playing field for local producers.

Despite these debt challenges, the broader market shows strong growth potential. Estimates suggest the Mexican pharmaceutical market is valued at approximately USD 20 billion to USD 22.6 billion in 2026, with projections indicating it could double by 2033. This growth is being driven by rising expenditure, innovation, and an aging demographic. Specifically, the medical device sector is seeing increased demand for technologies to manage chronic conditions, such as diabetes and cardiovascular disease, as the population of residents aged 60 or older continues to rise.